TCRX:NASDAQTScan Therapeutics, Inc. Analysis

TScan Therapeutics is trading at $0.91, well below its 20‑day (≈$1.00), 50‑day (≈$1.10) and 200‑day (≈$1.29) moving averages, with a bearish MACD crossover and an RSI of 35 that hints at oversold conditions. Volatility is extreme at nearly 59% over the past 30 days and a beta of 2.3 signals pronounced sensitivity to market swings; the stock is hovering just above its calculated support of $0.90 and faces resistance near $1.13. Valuation metrics are mixed: a price‑to‑book of 0.42 suggests a discount to net assets, while a price‑to‑sales of 6.5 and a negative earnings multiple reflect the challenges of a pre‑revenue, loss‑making biotech.
Fundamentally, revenue has collapsed by 55% to $9.1 M, operating margins are –29.7% and cash flow remains deeply negative, with $128 M in cash offset by $92 M of debt (debt‑to‑equity ≈ 95%). Recent earnings showed a modest profit‑beat (+1.1%) but a severe revenue miss (‑57.9%). The company’s pipeline is early‑stage (Phase I TCR‑T therapies) and hinges on future clinical success and its Amgen collaboration, underscoring high sector and regulatory risk.